Spectral Molecular Imaging, Inc., a medical imaging device company recently acquired by Cascade Technologies, is focused on developing non-invasive devices that use patented technology for improved clinical diagnostics, primarily in the field of cancer pathology. These devices utilize high-resolution imaging, identification, and analysis of certain molecular, cellular, and tissue features via spectral-imaging approaches. The company also plans to provide services related to its primary products, including software modules and maintenance services.
The company’s optical diagnostic products are being designed for operation in conjunction with surgical and/or evaluation procedures in real time. Spectral Molecular’s technology is anticipated to enable early detection and more reliable diagnosis of various diseases, such as Barrett’s esophagus, lung cancer, and melanoma. The end result will be significant improvement in long-term patient outcomes and substantial reduction in overall costs for the healthcare system.
Spectral Molecular was established by Daniel L. Farkas, Ph.D. and a group of others. While working at Carnegie Mellon University directing the Center for Light Microscope Imaging and Biotechnology, a national science and technology center, Dr. Farkas and his colleagues conducted development work and intellectual property protection on acousto-optic tunable filters for high-resolution, hyperspectral optical bioimaging. Spectral Molecular was formed to further develop and commercialize this approach and other optical molecular imaging technologies to save lives and improve patient outcomes.
Targeting multiple applications, end-user markets, and potential revenue streams, Spectral Molecular intends to develop three products: the MelaSpect™ device, the EndoSpect™ device, and the OxySpect™ device. These devices are being developed to address the early detection of skin cancer, to more accurately investigate tissue status during gastrointestinal and pulmonary endoscopy, and for mapping tissue oxygenation during and after surgical intervention, respectively.
Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net
Disclosure: no positions